Diabetes Drugs Market – Japan
Market Statistics
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 3.69% (2024-2032)
According to the IMARC Group, the Japan diabetes drugs market size is projected to exhibit a growth rate (CAGR) of 3.69% during 2024-2032. This market is driven by rising diabetes cases, increasing use of insulin therapies, oral hypoglycemics, and innovative GLP-1 receptor agonists, supported by government healthcare initiatives and policies.
Request For a PDF Sample Report: https://www.imarcgroup.com/japan-diabetes-drugs-market/requestsample
Japan Diabetes Drugs Market Trends and Drivers:
Growing diabetes prevalence and an aging population are driving market expansion.
Rising demand for innovative diabetes management solutions with better glycemic control and fewer side effects.
Introduction of new drug classes like SGLT2 inhibitors and GLP-1 receptor agonists revolutionizing treatment.
These drugs offer benefits beyond blood sugar control, such as weight loss and cardiovascular protection.
Government initiatives promoting diabetes prevention, early diagnosis, and treatment are key growth factors.
Pharmaceutical companies are focusing on R&D and partnerships with academic institutions for innovative therapies.
Digital health technologies, including glucose monitoring systems and mobile health apps, enhance diabetes management.
Japan Diabetes Drugs Market Segmentation:
The report has segmented the market into the following categories:
Breakup By Type:
Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic Drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Dopamine D2 Receptor Agonist
Bromocriptin
SGLT-2 Inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 Inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
Non-Insulin Injectable Drugs
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin)
Breakup By Distribution Channel:
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Breakup By Region:
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Buy Report: https://www.imarcgroup.com/checkout?id=15502&method=505
Key highlights of the Report:
Market Performance (2018-2023)
Market Outlook (2024-2032)
COVID-19 Impact on the Market
Porter’s Five Forces Analysis
Strategic Recommendations
Historical, Current and Future Market Trends
Market Drivers and Success Factors
SWOT Analysis
Structure of the Market
Value Chain Analysis
Comprehensive Mapping of the Competitive Landscape
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145